A personalized vaccine designed to target the unique genetic mutations of melanoma tumors has demonstrated a significant reduction in the risk of death from the disease, according to results from a late-stage clinical trial. The vaccine, known as intismeran, represents the first personalized cancer vaccine to show positive outcomes in a final-phase study.

The trial involved 1,137 patients who underwent surgery to remove their melanoma. All participants received the immunotherapy drug pembrolizumab (brand name Keytruda), while approximately two-thirds of the group were also administered the intismeran vaccine. Researchers found that the addition of the vaccine reduced the risk of melanoma recurrence or death by 42 percent compared to treatment with pembrolizumab alone.

Over a two-year follow-up period, the combined treatment showed a 38 percent decrease in the likelihood of the cancer spreading. The study, conducted by experts from the Melanoma Institute Australia, highlights the potential of personalized immunotherapy approaches, which tailor the vaccine to the specific tumor mutations present in each patient.

Intismeran was developed through a collaboration between pharmaceutical companies Merck Sharp & Dohme (MSD) and Moderna. Both companies indicated that this personalized vaccine platform is currently being investigated in clinical trials for other types of cancer, including kidney, bladder, and lung cancers.

These findings suggest a possible new direction in melanoma treatment, offering hope for improved survival outcomes using individualized vaccines alongside existing immunotherapy regimens. Further research is ongoing to confirm the broader applicability of this approach across multiple cancer types.